<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=1000083763474443&amp;ev=PageView&amp;noscript=1">

SmartTRAK Life Sciences News and Analysis Blog

SmartTRAK Life Sciences News and Analysis Blog in the Orthopedics, Wound, and Neuro Therapies Market Segments

Neuro Therapies

Trends in Neurovascular Innovation 2022

Improved aspiration systems, large-bore catheters, balloon-guide catheters and radial access top the lis...

Neuro Therapies

Partnering for Success in Neurovascular: Wallaby Medical

Wallaby Medical CEO and founder Michael Alper discusses the Company’s recent acquisition of phenox GmBH ...

Neuro Therapies

STIMVIEW XT: A New Approach to DBS Programming

Rafael Carbunaru, PhD, Boston Scientific’s VP of R&D, discusses DBS therapy and STIMVIEW XT, the Com...

Neuro Therapies

A Bumpy Ride: Q122 Spinal Cord Stimulation Market Recap

Q122 SCS Market revenues were up in the low-single digit YoY, but pandemic-related issues made it a bump...

Neuro Therapies

Opportunities in Neuromodulation: Abbott at INS 2022

Ryan Lakin, Abbott DVP of R&D, discusses opportunities in neuromodulation in an interview with Smart...

Neuro Therapies

INS 2022 Interview with Dr. Marc Russo: Dorsal Horn Dendrite Stimulation for SCS

Dr. Marc Russo discusses dorsal horn dendrite stimulation, a new paradigm for SCS, and making it availab...

Neuro Therapies

What’s New in Neuromodulation for Spring 2022

In the market for neuromodulation, companies are developing spinal cord stimulation (SCS), deep brain st...

Neuro Therapies

The State of Cybersecurity in Healthcare

Jason Winkler, Sales VP of cybersecurity startup Device Authority, discusses the state of cybersecurity ...

Neuro Therapies

Wallaby Acquires phenox GmBH

Wallaby Medical announced it has acquired phenox GmbH, including phenox's femtos GmbH, a German-based ne...

Neuro Therapies

Abbott: Expanding the Ecosystem in DBS - An Interview with Binith Cheeran

Abbott’s Binith Cheeran, MD, PhD discusses the latest trends in DBS as well as the Company’s strategies ...

1
...
4 5 6
...
14